LAUSR

&NA; In this investigation, the immunogenicity of HTLV‐1 fusion epitope‐loaded PLGA nanoparticles (NPs) was assessed in the absence or presence of co‐encapsulated CpG ODN adjuvant, in a mice model. For this purpose, the multi‐epitope chimera including Tax, env, and gag immunodominant HTLV‐1 epitopes was encapsulated in biodegradable PLGA NPs with or without CpG adjuvant. PLGA nanospheres produced by a double emulsion method had a size of <200 nm, and encapsulation efficiency of chimera antigen was 85%. The release profile of radiolabeled chimera indicated that only 17.4% and 20.1% of chimera were released from PLGA NPs without or with co‐encapsulated CPG ODN during one month, respectively. The PLGA formulations significantly elevated titers of IgG1, IgG2a, and sIgA antibodies, as well as IL‐10, and IFN‐&ggr; cytokines and also reduced the amount of TGF‐&bgr;1 production relative to the other vaccines. Additionally, co‐delivery of chimera and CpG ODN in PLGA NPs significantly promoted cellular and mucosal responses compared to the incorporation of CpG and chimera antigen. In summary, these results revealed that the sustained release of chimera from PLGA as an efficient polymeric system elicited potent cell‐mediated and mucosal immunity without inflammatory responses against HTLV‐1. Therefore, the proper design of vaccine formulation and immunization strategy are crucial factors to construct an efficient vaccine. Graphical abstract Figure. No caption available.